RayzeBio Funding & Investors
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
rayzebio.comTotal Amount Raised: $418,000,000
RayzeBio Funding Rounds
Series D
$160,000,000
Series D Investors
SofinnovaViking Global InvestorsWellington ManagementSands Capital ManagementLaurion Capital ManagementABGSoleus CapitalSeries C
$108,000,000
Series C Investors
Venrock Healthcare Capital PartnersTCG Crossover ManagementViking Global InvestorsCormorant Asset ManagementAlexandria Venture InvestmentsAcuta Capital PartnersVersant VenturesDeerfield ManagementvenBio PartnersVivo CapitalSamsara BioCapitalLifeSci Venture PartnersRedmile GroupOrbiMed AdvisorsLogos Global ManagementPerceptive AdvisorsSeries B
$105,000,000
Series B Investors
Venrock Healthcare Capital PartnersvenBio PartnersViking Global InvestorsRedmile GroupOrbiMed AdvisorsAlexandria Venture InvestmentsSamsara BioCapitalCormorant Asset ManagementLogos Global ManagementLifeSci Venture PartnersVersant VenturesSeries A
$45,000,000
Series A Investors
venBio PartnersVersant VenturesSamsara BioCapitalIPO
Unknown
Funding info provided by Diffbot.